Mitral regurgitation (MR) affects millions of patients worldwide. It is a progressive condition that can worsen when left untreated, possibly leading to compensatory remodeling of the left ventricle. This can result in reduced functional capacity, poor quality of life, repeat hospitalizations, and even death from heart failure. Open, arrested heart surgery has until now been the therapeutic treatment of choice. However, many high-risk patients cannot tolerate traditional heart surgery and continue to suffer from severe MR. In Percutaneous Mitral Leaflet Repair: MitraClip Therapy for Mitral Regurgitation, international experts discuss the clinical application of percutaneous mitral valve therapies for this subsect of patients, focusing on the MitraClip device. These new therapeutic developments will form an essential component of the interventional cardiologists' armamentarium in treating MR patients and will be of interest to every practicing cardiologist. Key topics include: An overview of the anatomy and pathophysiology of the mitral valvular complex and MR EVEREST trial outcomes, and the development of percutaneous edge-to-edge repair Updates on the global experience with this new therapy Patient selection and the role of percutaneous therapies for high-risk patients Echocardiographic guidance, including practical tips for the use of transesophageal echocardiography during a procedure Step-by-step techniques, plus tips and tricks for getting the best results for your patients Special considerations for treating the returning MR repair patient Discussion of the European experience since CE approval Future directions in percutaneous mitral valve therapies

The landscape of cardiac surgery is changing, as is the field of interventional cardiology. The idea of accessing and replacing a failing valve through the patients vasculature has become the most rapidly expanding therapy of choice in cardiovascular disease. Transcatheter Valve Therapies chronicles the astonishing advances that have taken place in the field and prepares readers for the challenging future of cardiac valve therapies. Designed to meet the growing needs of cardiologists, cardiac surgeons, anesthetists, and general practitioners, the book covers all aspects from logistic needs to clinical outcomes. It provides a comprehensive overview of transcatheter valve therapies and the necessary understanding for a successful clinical introduction at individual institutions. Topics include: Epidemiologic considerations Aspects of balloon aortic valvuloplasty as a stand-alone procedure or as part of the transcatheter valve replacement The history of how transcatheter valve therapies were implemented into surgical practice New imaging modalities The particularities of transcatheter access Aortic root anatomy Emerging technologies and future design improvements Development steps of aortic devices and potential solutions for transcatheter tricuspid, mitral, and pulmonary valve replacement The rigorous testing requirements for endovascular medical devices Clinical results of aortic transcatheter valve therapies in easy accessible text and table formats The future of transcatheter valve therapies All topics are discussed based on the author's own clinical and experimental experience in the field. This volume is essential for anyone involved in transcatheter valve implantation, clinicians wishing to become more involved in improving transcatheter valve therapies, and researchers engaged in building and creating new medical technologies to shape the cardiovascular landscape of the future.

Mitral regurgitation (MR) affects millions of patients worldwide. It is a progressive condition that can worsen when left untreated, possibly leading to compensatory remodeling of the left ventricle. This can result in reduced functional capacity, poor quality of life, repeat hospitalizations, and even death from heart failure. Open, arrested heart surgery has until now been the therapeutic treatment of choice. However, many high-risk patients cannot tolerate traditional heart surgery and continue to suffer from severe MR. In Percutaneous Mitral Leaflet Repair: MitraClip Therapy for Mitral Regurgitation, international experts discuss the clinical application of percutaneous mitral valve therapies for this subsect of patients, focusing on the MitraClip device. These new therapeutic developments will form an essential component of the interventional cardiologists' armamentarium in treating MR patients and will be of interest to every practicing cardiologist. Key topics include: An overview of the anatomy and pathophysiology of the mitral valvular complex and MR EVEREST trial outcomes, and the development of percutaneous edge-to-edge repair Updates on the global experience with this new therapy Patient selection and the role of percutaneous therapies for high-risk patients Echocardiographic guidance, including practical tips for the use of transesophageal echocardiography during a procedure Step-by-step techniques, plus tips and tricks for getting the best results for your patients Special considerations for treating the returning MR repair patient Discussion of the European experience since CE approval Future directions in percutaneous mitral valve therapies

This volume covers everything you need to know about atrial communications; the pathology, anatomy, physiology, and natural history of treated and untreated patients; indications for intervention; surgical techniques currently used to close such defects; and transcatheter closure of these defects using approved and investigational devices. It also presents imaging techniques for guiding such procedures--including transthoracic echo, tranesophageal echo, intracardiac echo, and 2-D and 3-D technology--and using MRI to evaluate patients. Every device currently available, both approved and nonapproved, is discussed in detail along with technical analyses of how to close defects. In addition to addressing the association between PFOs and strokes and migraines, the contributors examine the status of all trials addressing transcatheter closure of ASDs and PFOs.

The landscape of cardiac surgery is changing, as is the field of interventional cardiology. The idea of accessing and replacing a failing valve through the patients vasculature has become the most rapidly expanding therapy of choice in cardiovascular disease. Transcatheter Valve Therapies chronicles the astonishing advances that have taken place in the field and prepares readers for the challenging future of cardiac valve therapies. Designed to meet the growing needs of cardiologists, cardiac surgeons, anesthetists, and general practitioners, the book covers all aspects from logistic needs to clinical outcomes. It provides a comprehensive overview of transcatheter valve therapies and the necessary understanding for a successful clinical introduction at individual institutions. Topics include: Epidemiologic considerations Aspects of balloon aortic valvuloplasty as a stand-alone procedure or as part of the transcatheter valve replacement The history of how transcatheter valve therapies were implemented into surgical practice New imaging modalities The particularities of transcatheter access Aortic root anatomy Emerging technologies and future design improvements Development steps of aortic devices and potential solutions for transcatheter tricuspid, mitral, and pulmonary valve replacement The rigorous testing requirements for endovascular medical devices Clinical results of aortic transcatheter valve therapies in easy accessible text and table formats The future of transcatheter valve therapies All topics are discussed based on the author's own clinical and experimental experience in the field. This volume is essential for anyone involved in transcatheter valve implantation, clinicians wishing to become more involved in improving transcatheter valve therapies, and researchers engaged in building and creating new medical technologies to shape the cardiovascular landscape of the future.

The field of structural heart disease interventions is experiencing a stage of rapid growth with the development of percutaneous mitral valve repair therapies and percutaneous aortic valve replacement therapies. The MitraClip represents a new therapeutic frontier for mitral regurgitation and is expected to revolutionize repair of the mitral valve. For the first time in the world, physicians now have the capability to repair the mitral valve percutaneously without the need for a sternotomy or cardiopulmonary bypass. However, as with all new endeavors, there is a steep learning curve, not just for the individual operator but also for the entire field. The MitraClip technology and technique is technically complex and is guided by echocardiography and fluoroscopy. It is an imaging intensive procedure that requires deep 3-dimensional understanding of normal and abnormal cardiac anatomy. Not all mitral regurgitation cases are suitable and not all cases are straightforward. It is therefore crucially important for physicians in this specialty to communicate their experience, successes, failures and complications with each other. Written by the leaders in this breakthrough field, the Atlas of Percutaneous Edge-to-Edge Mitral Valve Repair is the first of its kind for the new percutaneous MitraClip procedure. The Editors have designed the book to be a comprehensive reference manual and to provide cardiologists with true examples of basic and complex cases of percutaneous mitral valve repair using the technology. In addition, this book provides step-by-step guides to the procedure and complications as well as steps to recover from them are discussed. The Atlas is anticipated to be a very valuable reference for both novice and experienced interventional cardiologists and echocardiologists. As percutaneous valve repair becomes more common it will also be of great interest to general cardiologists and surgeons.

Created by world-renown editors who have assembled a stellar team, a Who 's Who of pediatric and adult cardiologists, surgeons, and interventionalists who offer the reader pearls of wisdom based on daily practice in the cath lab, this practical guide discusses methods to overcoming complications in the interventional treatment of congenital and structural heart disease for invasive cardiologists in the pediatric and adult fields.

The advice of the text is practical, and full descriptions and illustrations are presented about current technology and how it has revolutionized the treatment of congenital and structural heart defects.

Transcatheter Valve Repair discusses all aspects related to percutaneous and established valve repair methods. The book is divided into few major sections covering all four valves and other topics. Each section contains several chapters discussing everything related to that valve. Beginning with the pulmonary valve, since it was the first valve to be tackled in the catheterization laboratory, and then moving to the aortic, then the mitral and then finally end with the tricuspid valve. 1.5M US citizens alone have some degree of aortic valve stenosis, with half (750K) requiring aortic valve replacement. Aortic valve replacement, on the whole, is performed by surgeons, requiring bypass machines and technicians, as well as the usual operating team. The operation is expensive and occupies a considerable amount of operating room time. Mostly, the aortic valve is calcified and the usual option available to patients is valve replacement with a variety of choices, ranging from porcine valves to synthetic, for which there are many manufacturers. It should be noted that the aortic valve is the most problematic of valves. Percutaneous procedures are the answer. The bottom line is that given the growing elderly population, many more patients will require valve repair, thus increasing health care costs with not only surgical operations but also hospitalisation. Percutanous valve repair, whilst requiring a cath lab team, does not involve bypass machines nor extended hospitalisation. Like percutaneous transluminal coronary artery interventions (PTCA) has replaced coronary artery bypass grafts (once the golden standard), and now stenting having replaced PTCA and its balloons. We now see drug eluting stents replacing ordinary stents (though at a much higher cost. There will be a huge movement toward percutanous valve repair, which should presumably cut costs but also morbidity and mortality.